TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of AggreGuide A-100 (ADP) Assay

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a history of cardiovascular disease OR~* Subject has 2 or more cardiac risk factors:~  * Smoking~ * Hypertension~ * Hyperlipidemia~ * Family History of Heart Disease~ * Post-menopausal female~ * Diabetes~ * Obesity (BMI \> 30)~ * Sedentary lifestyle~Exclusion Criteria:~Taken nonsteroidal anti-inflammatory drugs (NSAIDs) drugs, anti-platelet drugs or anticoagulant drugs within the past seven (7) days, over age 75, under 60 kg body weight, in the last trimester of pregnancy or breastfeeding, with a diagnosed history of: stroke or transient ischemic attacks, or other thromboembolic disease, anemia, thrombocytopenia, uncontrolled hypertension,platelet disorders,hemophilia or other bleeding disorder, gastrointestinal disease, severe renal disease, expect to engage in contact sports, scheduled for elective surgery, have a medical history as determined by the Investigator that would pose safety concerns, or possess contraindications for any of the study medications.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 74 Years
- Healthy Volunteers: t

Study Arms:
- Clopidogrel (Type: EXPERIMENTAL): Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days.
- Prasugrel (Type: EXPERIMENTAL): Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days.
- Ticagrelor (Type: EXPERIMENTAL): Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Magnesium and Ketamine in Postoperative Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with class II physical status (American Society of Anaesthesiologists) ,~* Age between 18-65 years,~* Scheduled for breast cancer surgery (e.g. modified radical mastectomy and conservative mastectomy)~Exclusion Criteria:~* Patient refusal,~* Cardiac dysfunction (ejection fraction \<45%),~* Diabetic patients~* Patients with uncontrolled hypertension~* Patients have any degree of heart block~* Patients have renal impairment (creatinine \> 2 mg/dl),~* Patients have hepatic dysfunction (transaminases \> 2 times normal),~* Patients with preexisting neurological or psychiatric disease,~* Patients who are allergic to one of the study drugs,~* Patients with communication difficulties,~* Inability to use the patient controlled analgesia (PCA) device,~* Female patients who are pregnant~* Patients who use preoperative calcium channel blockers or narcotic drugs.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ketamine group : group (k) (Type: EXPERIMENTAL): -Ketamine group (group K): will receive a bolus of 0.5 mg/kg ketamine during induction of anaesthesia diluted in 100 ml normal saline, followed by ketamine infusion 0.12 mg/kg/hour continued till 24 hours after surgery. The infusion pump concentration will be 0.6mg/ml and the rate of infusion will be 0.2 ml/kg/hour
- ketamine and magnesium group: group (KM) (Type: EXPERIMENTAL): - Ketamine and magnesium group (group KM): will receive a bolus of 0.5 mg/kg ketamine added to 50mg/kg magnesium sulfate diluted in 100 ml normal saline over 30 minutes after induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour added to 8mg/kg/hour of magnesium sulfate continued till 24 hours after surgery. Each ml of the administered infusion will contain 0.6mg ketamine and 40mg magnesium and the rate of infusion will be 0.2 ml/kg/hour.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adolescents and Adults ages 12-59 with a diagnosis of Schizophrenia, Schizoaffective Disorder, Schizophreniform, Bipolar I, Bipolar II, Bipolar NOS or Psychotic Disorder NOS, Autism Spectrum Disorder~* Patients will be currently treated with antipsychotics~Patients will qualify for entry if they meet the following weight criteria:~1. The patient has gained 7% of their weight since beginning of treatment with one or more of the current antipsychotics.~2. The patient has had an increase of 7% of their weight during the last year while being treated with antipsychotics.~3. The patient has a BMI of 30 or more and has gained 10 lbs or more in the past 8 months while being treated with antipsychotic medications.~4. The patient has a BMI of 35 or greater at the current time, and his chart shows a history of consistent weight gain over the past 1 to 3 years during treatment with antipsychotics.~   .~   Exclusion Criteria:~  * Subjects will be excluded if they have asthma, peptic ulcer disease (diseases which may be exacerbated by a histamine analog), or history of pheochromocytoma or peptic ulcer disease. Patients will be excluded if they are prescribed medications known to affect body weight or glucose-lipid metabolism, such as prescription or over the counter medications taken for the purpose of weight reduction. Subjects who are currently treated with metformin, for less than 6 months and have shown recent weight change on metformin. Patients on thyroid replacement therapy or lipid-lowering agents whose dosage has changed by more than 50 % in the past month will be excluded. If they are relatively stable doses of these medications they will not be excluded. Patients who are on lipid lowering medication, thyroid replacement medication, or diabetes medication, (excluding metformin), must remain on these medications throughout the period of the study. Females who are pregnant or breast feeding will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Subjects assigned to this arm will receive Betahistine.
- 2 (Type: PLACEBO_COMPARATOR): Subjects in this group will received placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 24-hour IOP-lowering Effect of 0.01% Bimatoprost

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* primary open-angle glaucoma or ocular hypertension~Exclusion Criteria:~* Women of childbearing potential previous glaucoma surgery presence of other eye disease

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 0.01% bimatoprost (Type: EXPERIMENTAL): bimatoprost 0.01% one time per day at bedtime for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 to 65 years;~* HBsAg seropositive status for more than 6 months prior to enrollment;~* never received treatment with any form of nucleos(t)ide analogues (NAs) or interferon before enrollment;~* Serum HBsAg ≤1500 IU/mL;~* HBeAg negative with or without HBeAb positive;~* Serum HBV DNA ≤2000IU/ml IU/mL;~* normal ALT levels;~* normal white blood cell and platelet counts;~* abdominal computed tomography or B-ultrasound showed no cirrhosis, splenomegaly or ascites.~Exclusion Criteria:~* Participants with other hepatotropic viruses or human immunodeficiency virus co-infection~* other chronic non-viral liver diseases or decompensated liver diseases~* tumours~* drug abuse~* severe psychiatric disease~* uncontrolled thyroid disease or diabetes~* pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): PegIFN α- 2b monotherapy, 180 μg/ week, 68 weeks of treatment, 24 weeks of follow-up after drug withdrawal
- Group B (Type: ACTIVE_COMPARATOR): Patients had a lead-in period of 16 weeks before baseline, pegifn α- 2b single drug treatment for 24 weeks, 4 weeks after drug withdrawal, 16 weeks of introduction period, pegifn α- 2b was followed up for 24 weeks. The plan of the induction period is as follows: 1) from the first day of the induction period, GM-CSF is injected subcutaneously ® one hundred μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd.), 100 μg/ day, 5 consecutive days, one cycle every 4 weeks, 4 consecutive cycles. 2) On the third day of the induction period, recombinant hepatitis B vaccine (Saccharomyces cerevisiae) (1.0ml/HBsAg 60 per dose) was injected subcutaneously μg. Shenzhen Kangtai Biological Products Co., Ltd.), 60 μ g. Once every 4 weeks for 4 consecutive cycles, the course of treatment was 68 weeks, and the patients were followed up for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Tisotumab Vedotin in Cervical Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Patients with extra-pelvic metastatic or recurrent cervical cancer including squamous cell, adenocarcinoma or adenosquamous histology who have experienced disease progressed on standard of care chemotherapy in combination with bevacizumab, if eligible.~* Measurable disease according to RECIST v1.1 as assessed by IRC.~* Age ≥ 18 years.~* Acceptable renal function~* Acceptable liver function~* Acceptable hematological status~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* A negative serum pregnancy test for patients of reproductive potential.~* All patients must provide a fresh or archival biopsy during screening.~* Following receipt of verbal and written information about the trial, patients must provide signed informed consent before any trial-related activity is carried out.~Exclusion Criteria~* Have received no more than 2 prior systemic treatment regimens for recurrent or metastatic cervical cancer.~* Known past or current coagulation defects leading to an increased risk of bleeding;~* Ongoing major bleeding~* Active ocular surface disease~* Known past or current malignancy other than the inclusion diagnosis.~* Peripheral neuropathy grade ≥ 2

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: EXPERIMENTAL): tisotumab vedotin (IV), 2.0 mg/kg, every 3 weeks (1Q3W)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rhopressa for Corneal Edema Associated With Fuchs Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Male or female patient diagnosed with FECD and corneal edema evident by slit lamp exam and/or corneal tomography.~* Patient is able and willing to administer eye drops.~* Patient is able to comprehend and has signed the Informed Consent form.~Exclusion Criteria:~* Active intraocular inflammation, corneal ulceration, keratitis, or conjunctivitis.~* Known sensitivity to any of the ingredients in the study medications.~* Abnormal eyelid function.~* History of herpetic keratitis.~* History of non-compliance with using prescribed medication.~* Current or planned pregnancy within the study duration.~* Concurrent involvement or participation in another randomized clinical trial within 30 days prior to enrollment in this study.~* Any ocular or systemic condition (i.e., UNCONTROLLED systemic disease) or situation which in the investigator's opinion may put the patient at significant risk, confound the study results, or interfere significantly with the patient's participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Netarsudil (Type: ACTIVE_COMPARATOR): A drop of Netarsudil 0.02% ophthalmic solution will be instilled into both eyes once daily at night.
- Placebo (Type: PLACEBO_COMPARATOR): A placebo eye drop, consisting of the vehicle for netarsudil ophthalmic solution without the active ingredient, will be instilled into both eyes once daily at night.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Positive qualitative hepatitis C virus RNA test on two occasions at least 6 months apart~* Renal failure (eGFR \< 30 cc/min) or under hemodialysis~Exclusion Criteria:~* Model for End-stage Liver Disease (MELD) score \> 20,~* Child's C (CTP score \> 12),~* Heart rate \< 50/min,~* Taking amiodarone

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sovodak (Type: EXPERIMENTAL): Sofosbuvir 400 mg and daclatasvir 60 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ceftobiprole in the Treatment of Patients With Community-Acquired Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients suffering from community-acquired pneumonia severe enough to require hospitalization~* Female patients must be postmenopausal for at least 1 year, surgically sterile, or practicing an effective method of birth control before entry and throughout the study~Exclusion Criteria:~* Patients with known or suspected hypersensitivity to any related antibiotic medications~* Treatment with any experimental drug within 30 days before enrollment~* Prior enrollment in this study or any study with ceftobiprole medocaril

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ceftobiprole medocaril (Type: EXPERIMENTAL): Ceftobiprole medocaril 500mg q8h as 2h infusions, 7-14d
- Ceftriaxone with or without Linezolid (Type: ACTIVE_COMPARATOR): Ceftriaxone 2g qd as 0.5h infusions with or without Linezolid 600mg q12h as 1h infusions, 7-14d

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metronidazole as an Adjunct of Non- Surgical Treatment of Peri-implantitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Older than 18 years.~* Presence of at least 1 implant diagnosed with peri-implantitis (Presence of BOP and/or suppuration, with 2 mm of detectable bone loss after initial remodeling, and PD≥ 4 mm as defined by Daubert et al. 2015).~* Absence of implant mobility.~* History of taking systemic antibiotics in the preceding 3 months.~* No systemic pathology that contraindicated the completion of treatment.~* The patient understands the treatment and willing to comply.~* The patient is willing to give written informed consent and can do~Exclusion Criteria:~* Pregnant.~* Metronidazole allergies~* Patients on treatment with bisphosphonates.~* Uncontrolled periodontal disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Metronidazole 250mg (Type: ACTIVE_COMPARATOR): Systemic antibiotic: Metronidazole 250mg , 2 capsules three times a day, for 7 days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo: same shape, size and dosis as test

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and Females, age 11-40~* Histologic evidence of EoE~* History of clinical symptoms of EoE including dysphagia~* Willing to continue with dietary, environmental or medical therapy~* Ability to read and understand english~* Written Consent~Exclusion Criteria:~* Any Medical condition that may compromise the safety of the subjects or interfere with the signs and symptoms of EoE~* Use of immunomodulatory therapy~* Current use of swallowed corticosteroids~* Esophageal strictures,varices or upper GI bleed~* Other current diseases of the GI tract~* Current viral infection or immunodeficiency condition~* Pregnancy~* Hypersensitivity to budesonide~* History of non compliance

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Oral Budesonide Suspension (Type: EXPERIMENTAL): Taken once or twice daily for up to 40 weeks
- Matching Placebo (Type: PLACEBO_COMPARATOR): Taken once or twice daily for 20 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Patient is blood group O+~* Anticipated to be hospitalized for at least 3 consecutive days after initial study transfusion~* Expected to require no more than 2 units of Fresh Whole Blood in the 3 days following randomization~* Agree to return to the hospital for the follow-up visits~* Women of Child Bearing Potential must have a negative pregnancy test within 72 hours before randomization when warranted and must agree to practice a medically acceptable contraception regimen or agree to abstain from heterosexual intercourse during their study participation.~* Patient or legally authorized representative has given written informed consent~Exclusion Criteria:~* Symptoms of clinical malaria (confirmed by microscopy)~* Patient has received antimalarial treatment within 7 days prior to randomization~* Fever (Central body temperature greater than 38.5°C)~* Massive bleeding expected to require more than two Fresh Whole Blood units within 3 days from randomization~* Transfusion(s) of a blood product within 1 month prior to randomization~* Acute or chronic medical disorder that, in the opinion of the investigator, would impair the ability of the patient to receive protocol treatment~* Previous treatment with other pathogen-reduced blood products~* Females who are pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mirasol (Type: EXPERIMENTAL): Transfusions with Mirasol-treated whole blood
- Control (Type: ACTIVE_COMPARATOR): Transfusions with untreated whole blood

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male/female with refractory diarrhea for at least 1 month, after normal extended work-up to exclude causes of diarrhea, not or not enough responding to standard anti-diuretics as evaluated by the investigator~* Patient mentally fit for completing a diary~Exclusion Criteria:~* Has already received a treatment with somatostatin analogues for the treatment of refractory diarrhea~* Had a weight of stool \< 600g in a 72hrs stool collection~* Has received a treatment with laxatives within the last week before study entry~* Suffers from IBS with alternating bowel habits and predominant constipation, suffers from infectious and/or inflammatory gastro-enteritis (colitis ulcerosa, crohn's disease and macroscopic colitis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lanreotide (Autogel formulation) Autogel 120mg (Type: EXPERIMENTAL): lanreotide (Autogel formulation) Autogel 120mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete